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Pacemaker-mediated tachycardia is a potential compli-
cation of atrioventricular (AV) universal DDD pace-
makers when retrograde ventriculoatrial (VA) conduc-
tion is slower than the postventricular-atrial refractory
period of the pulse generator. The propensity for pace-
maker-mediated tachycardia was noninvasivelyassessed
in 17 patients with a unipolar DDD pacemaker using
chest wall stimulation. Low amplitude stimuli were de-
livered to chest wall electrodes through a programmed
stimulator. Using this method, 13of the 17patients were
found to have absent VA conduction or VA conduction
time less than the postventricular-atrial refractory pe-
riod. In the four patients with noninvasively measured
VA conduction time greater than the postventrlcular-
atrial refractory period, sustained pacemaker-mediated
tachycardia was induced. Reprogramming of pacemaker
parameters prevented repeat induction of pacemaker-
Patients with a pacemaker that senses and paces in both the
atrium and ventricle (DDD pacemaker) are at risk for pace-
maker-mediated tachycardia (l-4). Pacemaker-mediated
tachycardia is a reentrant arrhythmia that utilizes normal
pacemaker function as the anterograde limb and ventricu-
loatrial (VA) conduction as the retrograde limb of the circuit.
Patients are at risk for pacemaker-mediated tachycardia if
retrograde VA conduction is slower than the postventricular-
atrial refractory period of the pulse generator. It is suggested
that invasive measurement of VA conduction before pace-
maker implantation may help identify those patients likely
to develop pacemaker-mediated tachycardia (5). Repro-
gramming of the atrial refractory period and other pace-
maker parameters may then allow more patients to continue
use of the DDD mode (4-6). This study evaluates a non-
invasive method of evaluating the integrity of VA conduc-
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mediated tachycardia in only one of four patients. The
three remaining patients had clinical pacemaker-me-
diated tachycardia and underwent pacemaker program-
ming to the DVI mede, A total of 13 patients continue
to use DDD mode after a mean follow-up period of 9.5
± 5.4 months.
Invasive measurement of VA conduction was per-
formed in 13of the 17 patients. The noninvasive method
accurately predicted the invasive measurement in each
case. Noninvasive evaluation of VA conduction accu-
rately predicts the propensity for pacemaker-mediated
tachycardia under a variety of clinical conditions. Serial
testing can be performed after pacemaker reprogram-
ming or drug intervention. Noninvasive evaluation of
retrograde VA conduction should predict most clinical
episodes of pacemaker-mediated tachycardia.
(J Am Coli Cardiol1985;5:1403-6)
tion and the propensity for pacemaker-mediated tachycardia
in patients with a DDD pacemaker.
Methods
Patients. The study group consisted of 17 patients re-
ferred for implantation of a DDD pacemaker (Table I) .
There were 4 women and 13 men with a mean age of 62 .7
years . The indications for permanent pacing included sick
sinus syndrome in II patients , heart block in 5 and carotid
sinus hypersensitivity in I.
Invasive measurements. Eight patients underwent in-
vasive electrophysiologic testing in the cardiac electrophy-
siology laboratory in the postabsorptive nonsedated state .
After informed consent was obtained, quadripolar pacing
catheters were inserted percutaneously through the femoral
vein or a cutdown through a brachial vein into the right
atrium and apex of the right ventricle. Intracardiac record-
ings were filtered at 30 to 500 Hz and displayed on an
Electronics for Medicine VRl2 oscilloscope. Recordings
were made at a paper speed of 50 mm/s. Incremental ven-
tricular pacing was performed beginning at a rate greater
than the sinus rate and continued until retrograde VA block
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Table 1. Patient Data
Age (yr) Pacemaker PVARP Invasive Noninvasive Final
Case & Sex Model Indication (rns) VAC (ms) VAC (ms) PMT Mode
I 56M 7000 SSS 155 250 250 Yes DVI
2 62F 7000 SSS 155 250 Yes DVI
3 31M 7000 AV block 155 340 380' No DDD
4 64F 7000A SSS 235 390 Yes DVI
5 69M 7000A SSS 235 200 None No DDD
6 66F 7000A SSS 235 None None No DDD
7 62M 7000A CSH 235 180 None No DVI
8 76F 7000A SSS 235 None None No DDD
9 12M 7000A SSS 235 None None No DDD
10 65M 7000A AV block 235 None None No DDD
II 52M 7000A SSS 235 None None No DDD
12 31M 7000A AV block 235 None None No DDD
13 76M 7000A SSS 235 None No DDD
14 89M 7005 SSS 155 None No DDD
15 73M 7005 AV block 155 None None No DDD
16 66M 7005 SSS 155 None None No DDD
17 56M 7005 AV block 155 None None No DDD
' No pacemaker-mediated tachycardia was demonstrated after reprogramming of the atrioventricular (AV) interval to 150 ms. CSH = carotid sinus
hypersensitivity; F = female; M = male; PMT = pacemaker-mediated tachycardia; PVARP = postventricular-atnal refractory period; SSS = sick
sinus syndrome; VAC = ventriculoatrial conduction lime.
occurred. The VA conduction time was measured as the
interval between the ventricular pacing art ifact and the initial
deflection recorded on the atrial electrogram .
Five patients had invasive measurements of VA conduc-
tion performed in the operating room using the implanted
atrial and ventricular leads. Atrial activity was sensed while
the ventricle was paced at 90 or 100 beats/min. The atrial
electrogram was recorded on a Medtronic 53 I I analyzer.
Four patients had no invasive measurement of VA conduc-
tion time.
All 17 patients had a unipolar DDD pacemaker inserted
using standard techniques. Fifteen patients had transvenous
implantation and two patients had epicardial implantation .
Neither patient with an epicardial pacemaker had an invasive
measurement of VA conduction time . The models of im-
planted pacemakers included a Medtronic 7000 in 3 patients,
a Medtronic 7000A in 10 and a Medtroni c 7005 in 4.
Technique for the noninvasive measurement of ret-
rograde VA conduction. After implantation. the patients
underwent noninvasi ve assessment of retrograde VA con-
duction using chest wall stimulation. Atrial sensitivity was
first programmed to the highest sensitivity , with ventricular
sensitivity programmed to the lowest sensitivity. This per-
mitted atrial but not ventricular sensing of the chest wall
stimuli. If possible , the atrial refractory period was pro-
grammed to its shortest value (model 7005 only). The pro-
grammed upper rate limit was set at its highest value and
the atrioventricular (AV) interval at 150 to 250 ms . Con-
sistent atrial tracking in the DDD mode was demonstrated
in all patients. Chest wall electrodes were applied to the
shoulder and fifth intercostal space ipsilateral to the site of
the pulse generator. One to six low amplitude stimuli were
del ivered to the chest wall electrodes through a programmed
digital stimulator (Bloom Associates). Stimuli were of 2 ms
durat ion and less than I rnA.
Retrograde VA conduction was measured as the first ven-
tricular paced RR interval after chest wall stimulation minus
the programmed AV interval. No VA conduction was de-
fined as absent VA conduction or a VA conduction time
shorter than the postventricular-atrial refractory period . If
VA conduction was present , chest wall stimulation was
repeated after reprogramming of DOD parameters. All pa-
tients continued use of the DDD mode unless problems such
as pacemaker-mediated tachycardia or loss of atrial sensing
developed .
Results
Invasive measurement of VA conduction. Thirteen of
the 17 patients had invasive evaluation of VA conduction .
In 8 of the 13 patients, invasive study in the electroph y-
siology laboratory revealed the presence of VA conduction
in three and its absence in five. Among the five patients
evaluated in the operat ing room, VA conduction was found
in only one. The mean value in the four patients with in-
vasively measured VA conduction time was 243 ± 71 ms.
Noninvasive evaluation of VA conduction. Chest wall
stimulation demonstrated the presence of a VA conduction
time greater than the postventricular-atrial refractory period
in 4 of the 17 patients. In these four patients, mean VA
conduction time was calculated as 318 :::!: 78 ms. Sustained
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Figure 1. Patient I. Recordings obtained after chest
wall stimulation. Thepacemaker was programmed to
the DDD mode with a lower rate of 60 beats/min,
upper rate of 175 beats/min and an AV interval of
250 ms. Electrocardiographic leads VI and II were
recorded along with an intracardiac bipolar electro-
gram from theright atrium (RA) . Thethird chest wall RA,+-Hr.H++-m++lt+i#++-I++t+l++-ltl+tH~~H-+++'H-+i-+I~++,t+ttHM+*H~
stimulus (S) is sensed by theatrial sensing amplifier
and triggers a ventricular output at the programmed
AV delay. Sustained pacemaker-mediated tachycar-
diadeveloped ata cycle length of500ms. Retrograde
VA conduction time, confirmed by simultaneous in-
tracardiac recordings. is 500 - 250 = 250 ms.
pacemaker-mediated tachycardia was provoked in all four
patients with a VA conduction time greater than the post-
ventricular-atrial refractory period (Fig. I and 2). Program-
ming the AV interval to ISO rns prevented repeat induction
of sustained pacemaker-mediated tachycardia in one of the
four patients. Invasive measurement showed that VA con-
duction time was greater than the postventricular-atrial re-
fractory period in two of the four patients with intact VA
conduction. Both patients had sustained pacemaker-me-
diated tachycardia provoked by the noninvasive method. In
13 patients, no VA conduction was demonstratedafter chest
wall stimulation. The noninvasivemethodof evaluating VA
conduction correctly predicted the invasively measured VA
conduction time in every case.
Follow-up. Clinical episodes of sustained pacemaker-
mediated tachycardia developed in all three patients in whom
repeat programming could not prevent induction of pace-
maker-mediated tachycardia with chest wall stimulation.
These patients underwent pacemaker programming to the
DVI mode. The remaining 14 patientsunderwentpacemaker
programming to the DDD mode. In I of the 14, the pacing
mode was changed to the DVI mode because of early loss
of atrial sensing. The DDD mode was continued in J3 pa-
tients who were followed up for a mean period of 9.5 ±
5.4 months. Noneof these patients had pacemaker-mediated
tachycardia.
Discussion
Pacemaker-mediated tachycardia is a potential compli-
cation of DDD pacemakers. It is likely to develop in patients
with intact VA conduction whose VA conduction time is
greater than the postventricular-atrial refractory period of
the pulse generator. VA conduction can be measured by
invasive electrophysiologic testing (7,8) or in the operating
room at the time of pacemaker implantation (5) . This mea-
surement can be used to predict which patients are at risk
for the development of pacemaker-mediated tachycardia. A
problem with this approach is that some patients are later
found to have intact VA conduction even though none was
detectable in the operating room (4,6) . Our noninvasive
methodfor evaluating retrogradeVA conduction using chest
wall stimulation is a safe and simple method of accurately
predicting the susceptibility to pacemaker-mediated tachy-
cardia inasmuch as it may be repeated under a variety of
clinical conditions.
Clinical correlation. In our 17 patients, 4 were iden-
tifiedby the noninvasivemethodto be at risk for pacemaker-
mediated tachycardia. In one of the four patients, the sus-
ceptibility to pacemaker-mediated tachycardiacould be con-
trolled by reprogramming to a shorter AV interval. When
the AV interval is shortened, the first ventricular paced RR
interval after chest wall stimulation is likewise shortened.
In this patient, pacemaker-mediated tachycardiapresumably
did not develop because the first paced RR interval after
chest wall stimulation was shorter and now fell within the
retrograde refractory period of the AV node. Therefore, VA
conduction did not occur and pacemaker-mediated tachy-
cardia did not develop. The other three patients who were
found to be at continued risk despite reprogramming had
clinical episodes of pacemaker-mediated tachycardia while
the DDD mode was used. These patients underwent repro-
gramming to the DVI mode. None of the patients who had
absent VA conductionas definedby the noninvasivemethod
had clinical pacemaker-mediated tachycardia after program-
ming to the DDD mode. Therefore, noninvasive evaluation
Figure 2. Patient 2. Two chest wall stimuli (S) were
delivered during sinusrhythm. ADDD pacemaker was
programmed to a lower rate of 60 beats/min. upper
rate of 175 beats/min and an AV interval of 150 ms.
Sustained pacemaker-mediated tachycardia was pro-
voked at a cycle length of 400 ms. Therefore, retro-
grade VA conduction time is 400 - 150 = 250 ms.
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of VA conduction accurately predicts which patients are at
risk for pacemaker-mediated tachycardia. Repeat testing after
reprogramming or drug therapy can assess the efficacy of
these interventions in preventing pacemaker-mediated
tachycardia.
Invasive evaluation identified intact retrograde VA con-
duction in 4 of I3 patients. In two patients (Cases 1 and
3), the VA conduction time was greater than the postven-
tricular-atrial refractory period of the implanted pulse gen-
erator. Both patients had sustained pacemaker-mediated
tachycardia induced by the noninvasive method. The non-
invasive method will not identify all patients with intact VA
conduction, but only those whose VA conduction time is
greater than the postventricular-atrial refractory period,
namely, those at risk for clinical pacemaker-mediated tachy-
cardia. In each case, the noninvasive determination of ret-
rograde VA conduction correlated with the invasive
measurement.
Calculation of noninvasive VA conduction time. The
noninvasive retrograde VA conduction time is calculated
indirectly as the difference between the first ventricular paced
RR interval after chest wall stimulation and the programmed
AV interval of the pulse generator. Chest wall stimulation
triggers ventricular pacing without atrial capture. The chest
wall stimulus is sensed by the atrial lead and triggers a
ventricular output at the programmed AV interval. Retro-
grade VA conduction will be recorded provided two con-
ditions are met: I) the retrograde conduction time is longer
than the postventricular-atrial refractory period of the pulse
generator so that the retrograde atrial deflection may be
sensed and trigger a ventricular output, and 2) the sum of
the retrograde conduction time and the AV interval is greater
than the upper rate limit (in ms). If the sum of these two
values is less than the upper rate limit (in ms), the pulse
generator will extend the AV interval so that the triggered
RR interval is at the upper rate limit. The indirectly cal-
culated VA conduction time would thus be falsely high. To
prevent errors in the noninvasive calculation of VA con-
duction time, one should program the atrial refractory period
to its lowest value, and the upper rate limit and AV interval
to their highest values.
Role of VA conduction. Retrograde VA conduction is
common in patients undergoing pacemaker implantation
(9,10). Hayes and Furman (5) detected VA conduction in
67% of patients with sinus node dysfunction and 14% of
patients with anterograde AV block at the time of pacemaker
insertion. Inasmuch as VA conduction is necessary to main-
tain pacemaker-mediated tachycardia, invasive measure-
ment of VA conduction has been recommended before im-
plantation of a DDD pacemaker. However, incremental right
ventricular pacing does not always predict which patients
have the capacity to conduct retrograde through the AV
node. Mahmud et al. (11) demonstrated the effects of AV
sequential pacing on facilitating retrograde VA conduction.
In addition, changes in autonomic tone may alter determi-
nations made in the operating room when the patient is
sedated (12). The main advantage of the noninvasive tech-
nique for the measurement of VA conduction is its ability
to test the patient under a variety of clinical conditions
including changes in pacing parameters and drug therapy.
Conclusion. DDD pacemaker should be used with cau-
tion in patients with intact retrograde VA conduction. Non-
invasive evaluation of retrograde conduction can detect which
patients are at risk for the development of pacemaker-me-
diated tachycardia. Serial testing is possible so that one can
test a variety of interventions such as reprogramming the
atrial refractory period or the AV delay or testing drugs that
may affect the ability to prevent pacemaker-mediated tachy-
cardia. The noninvasive technique of evaluating retrograde
VA conduction with chest wall stimulation should allow
more patients to use the DDD mode.
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